Enzo Biochem Awarded Two New U.S. Patents Relating to Genomic Analysis and DNA Diagnostics.

Business & High Tech Editors

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Jan. 10, 2000

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it has received two United States patents covering key areas applicable to genomic analysis and DNA diagnostics.

These patents cover technology relating to the detection and identification of genes using microarrays, as well as gene sequencing and technology that can be used to improve DNA probe diagnostics. Genomic analysis has become an important tool in the study of disease at the molecular level that could ultimately lead to the development of new approaches for diagnosis and treatment of disease.

U.S. Patent No. 5,998,135 covers aspects of the application of energy transfer in the identification and characterization of genetic material. In an energy transfer assay system, the specific signal is produced when energy is passed from a donor to an acceptor molecule. Enzo's energy transfer systems, because they are characterized by a substantially reduced background compared to standard fluorescence-based assay systems, have the ability to provide more sensitive and accurate identification of DNA in a specimen or on a microarray.

U.S. Patent No. 5,989,809 covers a homogeneous, or one-phase assay system for detecting DNA. In such a system, the test could be performed in a single tube, without a washing step. It is a simpler and therefore a more economical procedure than conventional assays, Enzo said.

"The issuance of these patents further strengthens Enzo's portfolio of intellectual properties in the area of genomic analysis and gene sequencing, as well as in diagnostics," said Dean Engelhardt, Ph.D., Senior Vice President of Enzo. "With approximately 200 patents issued, and a like number pending, our capabilities in genetic analysis and diagnostics are vast. Today's patent awards both represent areas of major commercial development, in which Enzo is even more strongly positioned."

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis, with approximately 200 patents worldwide, are sold to the medical research markets throughout the world. The Company's therapeutic division is conducting two human clinical trials, one for HIV-infected patients and one for patients infected with the hepatitis B virus. Other therapeutic applications of Enzo's proprietary technology are directed towards the treatment of cholesterol management, inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and diabetes.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.